State Street Corp Lowers Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

State Street Corp reduced its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 1.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,204,718 shares of the company’s stock after selling 53,915 shares during the period. State Street Corp’s holdings in Xeris Biopharma were worth $9,133,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in Xeris Biopharma by 23.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company’s stock worth $964,000 after purchasing an additional 80,015 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Xeris Biopharma by 4,512.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after purchasing an additional 15,929 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Xeris Biopharma by 6.9% during the second quarter. Rhumbline Advisers now owns 189,970 shares of the company’s stock worth $427,000 after purchasing an additional 12,332 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Xeris Biopharma by 33.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after acquiring an additional 342,300 shares during the last quarter. Finally, Asset Management Group Inc. increased its stake in Xeris Biopharma by 130.7% in the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

XERS has been the topic of several research analyst reports. HC Wainwright lifted their price target on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research report on Monday, November 11th. Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Monday, November 11th.

Xeris Biopharma Trading Up 0.9 %

NASDAQ:XERS opened at $3.50 on Friday. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.69 and a twelve month high of $3.87. The company has a market capitalization of $521.78 million, a P/E ratio of -7.78 and a beta of 2.65. The firm has a 50-day moving average price of $3.29 and a two-hundred day moving average price of $2.81.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.